4Suppliers
2Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

COMPASS Pathways plc (CMPS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

10Total relationships
3Distinct source URLs
7High confidence
0.848Average confidence
2026-10-29Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

COMPASS Pathways plc Suppliers

TickerNameConfidenceEvidence
TD-SECURITIES-USA-LLC TD-SECURITIES-USA-LLC 92% The Company was party to a Sales Agreement for its ATM offering program, dated October 8, 2021, with TD Securities (USA) LLC, or TD Cowen, under which the Company was able to issue and sell from time…
HTGC Hercules Capital, Inc. 90% The Amended Loan Agreement provides for five tranches of term loans in an aggregate principal amount of up to $150,000,000, consisting of (i) a term loan of $50.0 million which will be fully funded a…
HTGC Hercules Capital, Inc. 90% Reciprocal relationship from HTGC graph: Reciprocal relationship from CMPS graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from CMPS graph: Reciprocal relationship from HTGC g…
ATAI AtaiBeckley Inc. 72% Reciprocal relationship from ATAI graph: y technologies. Nualtis recognizes license and research and development revenue from the use of its proprietary drug delivery technologies in its customers' p…

COMPASS Pathways plc Customers

TickerNameConfidenceEvidence
HTGC Hercules Capital, Inc. 72% Reciprocal relationship from HTGC graph: Reciprocal relationship from CMPS graph: tion in mental health. The Company is developing its investigational COMP360 psilocybin treatment through Phase 3 cli…
HTGC Hercules Capital, Inc. 72% tion in mental health. The Company is developing its investigational COMP360 psilocybin treatment through Phase 3 clinical trials in Europe and North America for patients with treatment-resistant dep…

COMPASS Pathways plc Debt Obligations

InstrumentDescriptionConfidenceEvidence
CMPS-DEBT-8724 Xbrl Convertible 90% xbrl convertible detail from xbrl 2022-12-31.
CMPS-DEBT Debt stack $50.7M 90% Market cache reports total debt of $50.7M.
CMPS-DEBT-8723 Warrants outstanding: 37258000 90% xbrl warrant detail from xbrl 2025-12-31.

COMPASS Pathways plc Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for COMPASS Pathways plc.

COMPASS Pathways plc Ownership

HolderNameConfidenceEvidence
CMPS-OWNER-DEEP-TRACK-CAPITAL-LP Deep Track Capital, LP 90% 13F overlay lists Deep Track Capital, LP as top holder; 197 tracked holders.

COMPASS Pathways plc Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
ATAI AtaiBeckley Inc. 100.00 1 ['supplier']
MAZE Maze Therapeutics, Inc. 100.00 2
RCUS Arcus Biosciences, Inc. 100.00 2
REPL Replimune Group, Inc. 100.00 2
HTGC Hercules Capital, Inc. 100.00 1 ['customer', 'supplier']
IRON Disc Medicine, Inc. 100.00 2
ALT Altimmune, Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
ENGN enGene Therapeutics Inc. 100.00 2
SVRA Savara Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
KURA Kura Oncology, Inc. 100.00 2
VRDN Viridian Therapeutics, Inc. 100.00 2
MDGL Madrigal Pharmaceuticals, Inc. 100.00 2
PHGE BiomX Inc. 100.00 2
SGHT Sight Sciences, Inc. 100.00 2
OBIO Orchestra BioMed Holdings, Inc. 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
CYTOF Altamira Therapeutics Ltd. 50.00 2
MEOBF MESOBLAST LTD 50.00 2
🔐
CMPS
Unlock CMPS Supply Chain Data
Verified relationships include:
TD-SECURITIES-USA-LLCTD-SECURITIES-USA-LLCSupplier92%
HTGCHercules Capital, Inc.Supplier90%
HTGCHercules Capital, Inc.Customer72%
HTGCHercules Capital, Inc.Customer72%
+6 more relationships locked
Subscribe, View plans →